Tivic Health Achieves Major Manufacturing Milestone for Lead Drug Entolimod Amidst Financial Challenges

Tivic Health (TIVC) has achieved a 200-fold increase in manufacturing capacity for its lead drug candidate, Entolimod, a TLR5 agonist for treating Acute Radiation Syndrome, Neutropenia, and other cancer-related conditions. Despite operational advancements, the company faces significant financial challenges, including negative margins and declining revenue. Tivic Health is advancing towards cGMP production, essential for FDA approval, but financial health metrics reveal substantial operational inefficiencies and profitability issues.